Tumor News and Research

RSS

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors.

5 Aug 2015

Top cancer research organizations to sponsor International Cancer Immunotherapy Conference in New York

The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.

4 Aug 2015

EORTC study: Irradiation of regional nodes in breast cancer patients has marginal effect on overall survival

At a median follow-up of 10.9 years, an EORTC study has shown that irradiation of regional nodes in patients with stage I, II, or III breast cancer has a marginal effect on overall survival, the primary endpoint (at 10 years, overall survival was 82.3 % for regional irradiation versus 80.7% for no regional irradiation, (HR=0.87 (95%CI: 0.76, 1.00), p=0.06).

4 Aug 2015

California Initiative to Advance Precision Medicine selects two demonstration projects

Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr.

4 Aug 2015

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Adults who are worried or terrified sometimes curl up into a fetal position. Likewise, adult cells that are injured, including genetic injury leading to cancer, initiate a process that was present during embryonic development.

4 Aug 2015

Stress responder plays critical, early step in repairing DNA damage

DNA damage increases the risk of cancer, and researchers have found that a protein, known to rally when cells get stressed, plays a critical, early step in its repair.

4 Aug 2015

MD Anderson scientists reveal role of metabolic enzyme fumarase in DNA repair

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information published this week reveals more about why this occurs and how these breaks can be repaired.

4 Aug 2015

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Skin cancer is the most common of all cancers, and melanoma, which accounts for 2% of skin cancer cases, is responsible for nearly all skin cancer deaths. Melanoma rates in the US have been rising rapidly over the last 30 years, and although scientists have managed to identify key risk factors, melanoma's modus operandi has eluded the world of medical research.

4 Aug 2015

Scientists successfully test new tumor diagnosis method

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf, in cooperation with colleagues at the University of Zurich and the Ruhr-Universität Bochum, have for the first time successfully tested a new tumor diagnosis method under near-real conditions. The new method first sends out an antibody as a "spy" to detect the diseased cells and then binds to them.

4 Aug 2015

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.

4 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

BUSM researchers find new way to detect and treat basal-like breast cancer

A new way to detect - and perhaps treat - one of the deadliest types of breast cancer has been found. Led by researchers at Boston University School of Medicine (BUSM), the study appears online in Breast Cancer Research.

3 Aug 2015

Researchers quantify growth and composition of breast tumours in living animal

The ability to visualize and characterize the composition of a tumour in detail during its development can provide valuable insights in order to target appropriate therapeutics.

3 Aug 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015

Researchers uncover new mechanism that p53 protein uses to trigger cell death

Researchers have identified a new mechanism that the tumor suppressor protein p53 uses to trigger cell death via apoptosis and have shown how the process could be harnessed to kill cancer cells. St. Jude Children's Research Hospital scientists led the study, which appears today in the scientific journal Molecular Cell.

31 Jul 2015

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Daiichi Sankyo Europe and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor, a rare, locally aggressive neoplasm of the joint or tendon sheath.

31 Jul 2015

Prostate cancer discovery may improve treatment strategies

Scientists from Cancer Research UK have discovered that there are five different types of prostate cancer and have found a way of distinguishing between them. These findings could change how the condition is treated, providing more effective therapies where they are needed the most.

30 Jul 2015

Surgeons describe positive outcomes in kidney cancer patients treated with robotic IVC thrombectomy

Surgery is required when cancer of the kidney causes a Level III thrombus, or clot, to develop in the major vein leading back to the heart. Traditionally this complicated procedure, inferior vena cava (IVC) thrombectomy, is performed using a large open incision, primarily because the vein is often difficult to reach.

30 Jul 2015

Tumor News and Research

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Top cancer research organizations to sponsor International Cancer Immunotherapy Conference in New York

EORTC study: Irradiation of regional nodes in breast cancer patients has marginal effect on overall survival

California Initiative to Advance Precision Medicine selects two demonstration projects

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Stress responder plays critical, early step in repairing DNA damage

MD Anderson scientists reveal role of metabolic enzyme fumarase in DNA repair

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Scientists successfully test new tumor diagnosis method

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

Array Biopharma reports strong fourth quarter and full year 2015 financial results

RNA-binding protein ROQUIN regulates response to DNA damage

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

BUSM researchers find new way to detect and treat basal-like breast cancer

Researchers quantify growth and composition of breast tumours in living animal

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Researchers uncover new mechanism that p53 protein uses to trigger cell death

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Prostate cancer discovery may improve treatment strategies

Surgeons describe positive outcomes in kidney cancer patients treated with robotic IVC thrombectomy

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News